Secreted METTL9 Restricts Candida via PRA1 Methylation in Gu
2026-05-15
Host-Secreted METTL9 as a Cross-Kingdom Antifungal Effector in the Gut
Study Background and Research Question
The gastrointestinal tract is a dynamic ecosystem in which commensal and opportunistic fungi coexist with the host and its microbiota. Among these, Candida albicans is the most prevalent fungal pathogen implicated in mucosal infections, especially in immunocompromised individuals or those with underlying inflammatory conditions (Bao et al., 2026). The adaptability of C. albicans allows it to evade host immunity and exploit episodes of dysbiosis, leading to invasive disease if unchecked. The intestinal mucosa deploys a range of defenses—including antimicrobial peptides, mucins, and immune cell subsets—but the molecular diversity of these mechanisms and their ability to counter evolving fungal resistance remain incompletely defined. The central research question motivating this study is: Are there previously unrecognized, host-derived, secreted enzymatic defenses that directly sabotage fungal virulence factors and limit intestinal colonization?Key Innovation from the Reference Study
Bao et al. identify and characterize a secreted host histidine methyltransferase, METTL9, as an unorthodox cross-kingdom antifungal effector (Bao et al., 2026). Unlike classical antimicrobial peptides or immune cell-derived factors, METTL9 is secreted by intestinal epithelial cells (IECs) into the gut lumen in response to C. albicans exposure. The enzyme specifically targets the fungal zinc-scavenging protein PRA1, catalyzing its histidine methylation. This post-translational modification impairs PRA1's function in zinc acquisition, a process essential for fungal growth and virulence. By deploying a catalytic mechanism that disrupts a key fungal nutrient pathway, METTL9 expands the repertoire of mucosal antifungal strategies and reveals a catalytic sabotage model that bypasses established resistance routes.Methods and Experimental Design Insights
The study employed a combination of in vivo, ex vivo, and in vitro approaches to unravel the antifungal function of METTL9:- Proteomic Profiling: The authors profiled the secretome of IECs after exposure to C. albicans, revealing a marked induction of METTL9. Mass spectrometry and immunoblotting confirmed its secretion into the intestinal lumen (Bao et al., 2026).
- Fungal Protein Target Identification: Pull-down assays and binding studies established that METTL9 directly interacts with PRA1, a known fungal zincophore.
- Enzymatic Assays: In vitro methylation assays demonstrated METTL9’s ability to methylate specific histidines on PRA1, confirmed by mass spectrometric mapping of modified residues.
- Functional Consequence Evaluation: The impact of PRA1 methylation on zinc binding and uptake was quantified using zinc-binding assays and fungal growth studies under zinc-limited conditions.
- Animal Models: Mouse models of intestinal candidiasis were used to assess the role of METTL9 in restricting C. albicans colonization and dissemination, including METTL9 knockout and overexpression systems.
- Clinical Correlation: Colonic mucosal biopsies from patients with inflammatory bowel disease (IBD) were analyzed for METTL9 expression and C. albicans abundance, correlating host METTL9 status with fungal load.
Core Findings and Why They Matter
The paper’s central findings provide a mechanistic and translational advance in our understanding of mucosal antifungal defense:- Inducible Secretion of METTL9: IECs upregulate and secrete METTL9 in response to C. albicans, positioning it as a frontline antifungal effector (Bao et al., 2026).
- Direct Targeting of Fungal PRA1: METTL9 binds and methylates PRA1, which is essential for zinc acquisition in C. albicans and other pathogenic fungi.
- Methylation Impairs Fungal Zinc Uptake: Modified PRA1 loses its ability to bind and import zinc efficiently, resulting in a nutritional blockade that restricts fungal growth and colonization.
- Host Defense Bypasses Drug Resistance: Since this mechanism targets a nutrient acquisition pathway rather than classical antifungal targets (e.g., membrane synthesis), it remains effective even in multidrug-resistant Candida species such as C. auris (which retains PRA1).
- Clinical Correlation in IBD: Lower METTL9 expression in IBD patients is associated with higher intestinal C. albicans burden, suggesting a role for METTL9 in maintaining human gut mycobiota homeostasis.
Comparison with Existing Internal Articles
Recent internal resources, such as the workflow guide on Fluconazole as a Fungal Cytochrome P450 Inhibitor: Applied Workflows, emphasize the centrality of ergosterol biosynthesis inhibition and antifungal susceptibility testing in experimental mycology. Fluconazole, a triazole-based antifungal, acts as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor, disrupting ergosterol biosynthesis and compromising membrane integrity (internal article). These resources provide actionable protocols for leveraging fluconazole in the assessment of drug resistance and pathogenesis in C. albicans, and highlight the role of autophagy and protein phosphorylation in biofilm resistance (PP2A-Mediated Autophagy in Candida albicans Biofilm Resistance). In contrast, the METTL9 study advances a complementary paradigm: rather than targeting membrane synthesis, the host sabotages fungal nutrient acquisition via enzymatic modification. While antifungal susceptibility testing with compounds like fluconazole remains essential for dissecting drug resistance mechanisms, the METTL9 findings suggest that future research could integrate host-derived effectors into antifungal screening platforms, especially for resistant clinical isolates.Limitations and Transferability
Despite its innovative insights, the study carries several limitations:- Host-Fungal Specificity: The catalytic defense mechanism is contingent on the presence of PRA1 or homologous zincophores in the fungal pathogen. Fungi lacking PRA1 may not be susceptible to METTL9-mediated sabotage (Bao et al., 2026).
- In Vivo Complexity: Mouse models, while informative, may not fully capture the complexity of human gut mucosal immunity or the spectrum of IBD-associated dysbiosis.
- Clinical Translation: While lowered METTL9 correlates with increased fungal burden in IBD mucosa, causality and therapeutic potential require further study, including the feasibility of exogenous METTL9 supplementation or modulation.
- Broader Antifungal Relevance: The study does not address whether similar methyltransferase-based defenses operate against other classes of fungal pathogens beyond Candida spp.
Protocol Parameters
- in vitro fungal growth inhibition | 10 μg/mL fluconazole | Candida albicans SC5314 | Standard for antifungal susceptibility testing | product_spec
- animal model dosing | 80 mg/kg/day fluconazole, intraperitoneal | Mouse candidiasis model | Reduces fungal burden in vivo | product_spec
- protein methylation detection | mass spectrometry | PRA1 methylation by METTL9 | Validates histidine modification | paper
- clinical biopsy analysis | METTL9 mRNA/protein quantitation | IBD patient tissue | Assesses correlation with fungal load | paper
- solubility optimization | dissolution in DMSO ≥10.9 mg/mL, ethanol ≥60.9 mg/mL | Fluconazole stock preparation | Ensures reproducible dosing | workflow_recommendation